Nine more pharmaceutical companies signed pricing agreements with the White House on August 31, and the administration says the group is committing at least $19.6 billion to new manufacturing inside the United States as part of the deal. The signings raise the number of manufacturers under the administration’s most-favored-nation pricing framework to 26, a group the White House says now covers 89 percent of the branded prescription drug market. For an older reader managing a fixed income and a shelf of prescriptions, the manufacturing pledge is a separate promise from a lower price at the pharmacy counter, and the gap between the two is worth understanding before either number gets repeated as settled fact.
Nine Manufacturers Join the Most-Favored-Nation Roster
The nine companies are Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals and UCB, all mid-sized manufacturers rather than the largest global drug makers. Each signed a most-favored-nation, or MFN, pricing agreement tying its U.S. prices for new drugs to the lowest price it charges in other wealthy nations. The administration says the drugs involved treat hemophilia, Parkinson’s disease, macular degeneration, glaucoma, liver disease, skin conditions and several forms of cancer, conditions that show up often on Medicare drug plans for retirees. The new agreements also extend MFN pricing on the nine companies’ products to every state Medicaid program in the country.
With this round, the administration counts 26 manufacturers under MFN agreements, a total the White House fact sheet published August 31 says covers 89 percent of the branded drug market. The push began with a first agreement, with Pfizer, on September 30, 2025. It added nine more agreements on December 19, 2025, then Regeneron on April 23, 2026, before the August 31 signings brought in the nine companies above. Other manufacturers already under MFN deals include Pfizer, AstraZeneca, Eli Lilly, Novo Nordisk, Amgen, Bristol Myers Squibb, Merck, Johnson & Johnson and AbbVie, names that appear on many retirees’ pharmacy labels.
Free retirement updates: One number can cost or save hundreds a month in retirement. The free Retirement Shield newsletter surfaces the ones worth knowing. Sign up free.
What the $19.6 Billion Pledge Actually Buys
The manufacturing figure is separate from the pricing commitments. According to the fact sheet, the nine companies pledged to invest at least $19.6 billion collectively in U.S. manufacturing “in the near term,” language that sets no fixed completion date or facility list. Several of the companies also agreed to donate raw drug ingredients to the government’s Strategic Active Pharmaceutical Ingredients Reserve, intended to reduce reliance on foreign suppliers. UCB committed 163 tons of the anti-seizure drug levetiracetam; Sun Pharma pledged 71.4 tons of the antibiotic clindamycin and 6.75 tons of doxycycline; Teva committed 45 metric tons of the antibiotic metronidazole and 4.8 tons of the blood-pressure drug amlodipine; and Astellas pledged 25 kilograms of the anti-rejection drug tacrolimus. Those contributions build a stockpile for supply emergencies. They do not, on their own, change what a beneficiary pays for a monthly prescription.
A Pledge, Not an Audited Price Tag
Both the $19.6 billion figure and the 89 percent market-coverage claim come from the White House itself; neither has been independently audited by an outside accounting firm or verified against actual construction spending. The legal basis for these deals traces to Executive Order 14297, signed May 12, 2025, which directed the Department of Health and Human Services to communicate MFN price targets to manufacturers and authorized additional steps, including drug importation rulemaking and antitrust referrals, if manufacturers did not respond. That order created leverage for negotiation; it did not itself set a price a pharmacist can look up. The MFN agreements are also a different track entirely from the Medicare Drug Price Negotiation Program that Congress created by statute, under which the Centers for Medicare & Medicaid Services directly negotiates binding prices for a government-selected list of drugs. CMS says manufacturers for the third cycle of that program had a statutory deadline of February 28, 2026, to agree to negotiate, and any prices reached through that process take effect in 2028. Nothing in the August 31 fact sheet changes that separate timeline.
The Administration’s Own Savings Math
The fact sheet credits the broader MFN push, not just the August 31 signings, with producing more than $700 million in savings for patients using the federal TrumpRx.gov purchasing site since it launched in February 2026. It also cites the White House Council of Economic Advisers’ estimate that MFN deals as a whole will save $600 billion over the next decade, a projection rather than money already banked. The pledge also applies only to brand-name products made by these nine companies; it says nothing about the vastly larger number of generic prescriptions that make up most of what an older reader in Medicare actually fills, since the administration’s own materials define this program by these mid-sized brand manufacturers alone. Retirees who want to confirm whether a price has actually moved at a specific pharmacy can check a drug’s listing on TrumpRx.gov directly, since that site publishes current cash prices rather than pledged investment totals. The administration frames the manufacturing pledge as evidence the deals are durable enough for companies to build around, but the fact sheet dated August 31, 2026, remains the only public accounting of the $19.6 billion figure, and it is the administration’s own document rather than an independently verified ledger.
This article was produced with the assistance of AI and reviewed by The Financial Wire editorial team.
More Financial Reading
- Bank statements: how long to keep them and when to toss them
- What really happens to your joint savings account when you die?
David M. Keller is a finance writer based in Columbus, Ohio, covering personal finance and consumer-focused economic topics. He earned his degree in journalism from Ohio University and began his career reporting on local business and economic trends for a regional media outlet. Since then, he has contributed to a variety of online publications, focusing on clear, practical coverage of topics such as cost of living, debt, and everyday financial decision-making.
